Literature DB >> 7492437

Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.

Y Rivière1, M B McChesney, F Porrot, F Tanneau-Salvadori, P Sansonetti, O Lopez, G Pialoux, V Feuillie, M Mollereau, S Chamaret.   

Abstract

The duration of human immunodeficiency virus (HIV-1) infection prior to the development of AIDS is variable, and for most patients the exact time of infection is not known. A group of 38 HIV-1-infected subjects was tested while asymptomatic for comparative cytotoxic lymphocyte responses to the Gag and envelope antigens of HIV-1. Twenty of the 38 patients had no detectable primary cytotoxic T lymphocyte (CTL) response to Gag, and this was associated with a relative risk of 1.89 for progression to ARC or AIDS during the subsequent 3 to 40 months of observation when compared with patients who had Gag-specific CTL activity at the beginning of the observation period. In contrast, no significant association was observed between envelope-specific cytotoxic activity and disease progression. Other patient characteristics, including CD4+ T lymphocyte counts and antibody levels to the p24gag protein, measured at the start of observation, did not correlate with disease progression during the observation period. This suggests that the anti-Gag CTL response may be protective during HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492437     DOI: 10.1089/aid.1995.11.903

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  57 in total

1.  Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Authors:  G S Ogg; S Kostense; M R Klein; S Jurriaans; D Hamann; A J McMichael; F Miedema
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease.

Authors:  R Salerno-Gonçalves; W Lu; J M Andrieu
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.

Authors:  P J Goulder; C Brander; K Annamalai; N Mngqundaniso; U Govender; Y Tang; S He; K E Hartman; C A O'Callaghan; G S Ogg; M A Altfeld; E S Rosenberg; H Cao; S A Kalams; M Hammond; M Bunce; S I Pelton; S A Burchett; K McIntosh; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Authors:  P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

Authors:  Jacques Fellay; Nicole Frahm; Kevin V Shianna; Elizabeth T Cirulli; Danilo R Casimiro; Michael N Robertson; Barton F Haynes; Daniel E Geraghty; M Juliana McElrath; David B Goldstein
Journal:  J Infect Dis       Date:  2011-01-28       Impact factor: 5.226

6.  Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.

Authors:  Otto O Yang; Eric S Daar; Hwee L Ng; Roger Shih; Beth D Jamieson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-18       Impact factor: 2.205

7.  Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS.

Authors:  E L Delwart; H Pan; H W Sheppard; D Wolpert; A U Neumann; B Korber; J I Mullins
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

8.  Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells.

Authors:  Nami Iwamoto; Naofumi Takahashi; Sayuri Seki; Takushi Nomura; Hiroyuki Yamamoto; Makoto Inoue; Tsugumine Shu; Taeko K Naruse; Akinori Kimura; Tetsuro Matano
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

9.  Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic.

Authors:  Lara Vojnov; Jason S Reed; Kim L Weisgrau; Eva G Rakasz; John T Loffredo; Shari M Piaskowski; Jonah B Sacha; Holly L Kolar; Nancy A Wilson; R Paul Johnson; David I Watkins
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

10.  Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Authors:  D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.